Willem Mulder, Mount Sinai/AMC

Title: Nanomedicine and imaging for the management of inflammatory atherosclerosis
Session: Tuesday 6 October, 10:30

Abstract

Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, United States

Atherosclerosis is a chronic progressive disease, affecting the medium and large arteries, which is the underlying cause of myocardial infarction and stroke. Bioengineering provides unique opportunities to better understand and manage atherosclerotic disease. Twenty-first century innovations in diagnosing and treating atherosclerosis are the result of integrating cardiovascular medicine, immunology, medical imaging, bioengineering, and (bio)chemical engineering. The field is entering a new era that merges the latest biological insights into inflammatory disease processes with targeted imaging and nanomedicine. Ideally, nanotechnology will guide drug delivery to culprit cells and plaque, while preclinical cardiovascular molecular imaging allows the in vivo study of such nanotherapeutics specifically directed toward immune system components that drive atherosclerotic plaque development and complication. At the same time, recent successes in multimodality imaging integration in multicenter trials pave the way for anti-atherosclerosis nanotherapy evaluation in human subjects.

 

 

Bio

Willem Mulder's laboratory focuses on the development of nanoparticle libraries with differential specificity for processes relevant to disease progression. Nanoparticle materials from these libraries can be loaded with drugs, enabling targeted therapy of a variety of pathophysiological processes. For molecular imaging purposes, nanomaterials from immune cell screens are selected and labeled for highly sensitive and quantitative PET/MR imaging. Dr. Mulder has established a program that is aimed at applying nanomedicine to better understand, diagnose and treat inflammatory atherosclerosis in mouse models, and translating cardiovascular imaging and targeted nanotherapy to large animal models, i.e. rabbits and pigs, and ultimately humans.

 

 

 

Video Willem Mulder - Nanomedicine (Universiteit van Nederland)

 

 

Powered by Invitado Visitor Management